Estrella Immunopharma Treats First Patient with Two EB103 Infusions in STARLIGHT-1 Dose-Expansion Phase
Estrella Immunopharma dosed the first patient with two EB103 infusions three weeks apart at the recommended Phase II dose in the STARLIGHT-1 expansion phase, with no treatment-related serious adverse events through the first month. In the prior dose-escalation phase, EB103 achieved a 100% complete response rate at Month 1 in all evaluable high-dose cohort patients, with no treatment-related SAEs among the nine patients treated, and CRs held at the 9-month assessment in evaluable patients without CNS involvement.
Key figures
- Drug Name
- EB103
- Phase Of Trial
- Phase I/II (dose-expansion)
- Dose
- 5 × 10⁶ EB103 T cells/kg per infusion, two infusions three weeks apart
- Nct id
- NCT06343311
- Treatment related saes
- 0
- Cr rate dose escalation
- 100% complete response rate at Month 1 in all evaluable high-dose cohort patients
- Patients treated escalation
- 9
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.